(NASDAQ: VCYT) Veracyte's forecast annual revenue growth rate of 6.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.64%.
Veracyte's revenue in 2026 is $581,782,000.On average, 14 Wall Street analysts forecast VCYT's revenue for 2026 to be $48,611,764,107, with the lowest VCYT revenue forecast at $46,025,473,973, and the highest VCYT revenue forecast at $50,668,691,892. On average, 14 Wall Street analysts forecast VCYT's revenue for 2027 to be $52,200,292,102, with the lowest VCYT revenue forecast at $48,556,084,226, and the highest VCYT revenue forecast at $57,676,287,375.
In 2028, VCYT is forecast to generate $56,149,528,894 in revenue, with the lowest revenue forecast at $51,403,020,760 and the highest revenue forecast at $62,610,815,977.